CPRX Stock - Catalyst Pharmaceuticals, Inc.
Unlock GoAI Insights for CPRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $491.73M | $398.20M | $214.20M | $140.83M | $119.07M |
| Gross Profit | $422.89M | $346.24M | $179.81M | $118.95M | $102.03M |
| Gross Margin | 86.0% | 86.9% | 83.9% | 84.5% | 85.7% |
| Operating Income | $195.12M | $86.81M | $101.84M | $52.38M | $41.30M |
| Net Income | $163.89M | $71.41M | $83.08M | $39.48M | $74.98M |
| Net Margin | 33.3% | 17.9% | 38.8% | 28.0% | 63.0% |
| EPS | $1.38 | $0.67 | $0.80 | $0.38 | $0.72 |
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Visit WebsiteEarnings History & Surprises
CPRXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $0.42 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.51 | $0.68 | +33.3% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.58 | $0.68 | +17.2% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.53 | $0.68 | +28.3% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $0.32 | $0.70 | +118.7% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.49 | $0.57 | +16.3% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $0.42 | $0.56 | +33.3% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $0.34 | $0.38 | +11.8% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $0.48 | $0.53 | +10.4% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.24 | $-0.24 | 0.0% | = MET |
Q3 2023 | Aug 9, 2023 | $0.25 | $0.33 | +32.0% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $0.32 | $0.26 | -18.8% | ✗ MISS |
Q1 2023 | Mar 15, 2023 | $0.21 | $0.22 | +4.8% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $0.19 | $0.20 | +5.3% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $0.17 | $0.20 | +17.6% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $0.14 | $0.12 | -14.3% | ✗ MISS |
Q1 2022 | Mar 16, 2022 | $0.12 | $0.09 | -25.0% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $0.10 | $0.10 | 0.0% | = MET |
Q3 2021 | Aug 9, 2021 | $0.09 | $0.16 | +77.8% | ✓ BEAT |
Latest News
Frequently Asked Questions about CPRX
What is CPRX's current stock price?
What is the analyst price target for CPRX?
What sector is Catalyst Pharmaceuticals, Inc. in?
What is CPRX's market cap?
Does CPRX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CPRX for comparison